In a significant move within the pharmaceutical industry, Roche has brought on board a key executive from Novo Nordisk. This hire comes as part of Roche’s strategy to bolster its efforts in developing treatments for obesity. The executive, whose identity remains undisclosed, is expected to play a pivotal role in this initiative. This development follows a trend where 75% of Novo Nordisk’s top executives have transitioned to other major pharmaceutical companies in the past year, highlighting the competitive landscape for talent in the obesity drug market. Roche’s decision underscores the company’s commitment to expanding its portfolio in this rapidly growing sector, where the demand for effective obesity treatments is on the rise.
Holden Culotta
@Holden_Culotta
·
Oct 19, 2024 RFK Jr: Novo Nordisk is “counting on selling Ozempic to Americans because we’re so stupid and so addicted to drugs”
“It’s now the biggest company in Europe, but they’re not marketing it in Europe.”
@RobertKennedyJr
Novo Holdings
@novoholdings
·
Mar 5 Novo Holdings is pleased to announce the appointment of Chen Lichtenstein to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments.
With extensive leadership experience
Voice Of Healthcare
@vohglobal
·
3h Update
Roche Hires Novo Nordisk Executive as It Expands into Obesity Drug Market
#obesity #antiobesity #leadership #pharma #drugs
@Roche
http://voiceofhealthcare.org/updates/Roche-Hires-Novo-Nordisk-Executive-as-It-Expands-into-Obesity-Drug-Market~oq8_A0JuRbCM4aUN-akJF…
Reuters Business
@ReutersBiz
·
17h Novo Nordisk revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge https://reut.rs/3QVOLsa
Reuters Asia
@ReutersAsia
·
16h Novo Nordisk revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge https://reut.rs/3QVOLsa
More Perfect Union
@MorePerfectUS
·
Sep 24, 2024 Novo Nordisk’s CEO tried to blame pharmacy benefit managers for Ozempic’s high cost.
But
@SenSanders
called his bluff, and revealed he got written commitments from PBMs not to penalize Novo Nordisk if drug prices dropped.
Novo’s CEO still wouldn’t commit to lowering prices.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
